PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 29, 2012European Heart Journal146 citationsOpen Access

Mid-regional pro-atrial natriuretic peptide and pro-adrenomedullin testing for the diagnostic and prognostic evaluation of patients with acute dyspnoea

View Full Paper
RSRavi V. ShahQTQuynh A. TruongHGHanna K. Gaggin

Structured PICO

Does MR-proANP and MR-proADM testing improve the diagnostic and prognostic evaluation in patients with acute dyspnoea?

P
Population
patients with acute dyspnoea
I
Intervention
Mid-regional pro-atrial natriuretic peptide (MR-proANP) and pro-adrenomedullin (MR-proADM) testing
O
Outcome
diagnosis of acute decompensated heart failure (ADHF) and prognosis

MR-proANP and MR-proADM testing provides diagnostic accuracy for ADHF and independent prognostic value up to 4 years in patients presenting with acute dyspnea.

Abstract

Among patients with acute dyspnoea, MR-proANP is accurate for diagnosis of ADHF, while both MR-proANP and MR-proADM are independently prognostic to 4 years of the follow-up.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Shah et al. (2012) studied this question.

synapsesocial.com/papers/69dca00c867a001cf535915ahttps://doi.org/10.1093/eurheartj/ehs136
Ask AI
Helpful
Bookmark
Share
View Full Paper